Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-07Clinical Trial Update: Prevalence, Management and Follow-up of Patients With Addiction to Opioid Analgesics
A completed clinical trial update on the prevalence, management, and follow-up of patients with opioid analgesic addiction.
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access [Phase 1, Phase 2]
This update reports interim results from Phase 1/2 trials evaluating buprenorphine, combined with technology-enabled access to care, to addr…
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
A completed clinical trial assessing fetal neurobehavioral development in pregnancies maintained on methadone for opioid use disorder.
-
CLINICAL_TRIALS trial_result · 2018-04-24Clinical Trial Update: Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder [Phase 2]
Phase 2 study evaluating whether injections of buprenorphine can block opioid effects in individuals with opioid use disorder; results were …
-
CLINICAL_TRIALS trial_result · 2018-04-23Clinical Trial Update: Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients [NA]
The trial evaluated buprenorphine as a safe alternative for opioid-dependent patients with pain; the study was terminated and results were p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Automated Prize-based Contingency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients [EARLY_Phase 1]
An early-phase study evaluating automated prize-based contingency management to increase counseling attendance among patients receiving opia…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Effect of Clonidine on Responses to Imagery Scripts [Phase 1]
A Phase 1 trial evaluating clonidine’s impact on responses to imagery scripts in cocaine use disorder and opioid use disorder has completed.
-
CLINICAL_TRIALS research · 2018-04-05Clinical Trial Update: Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study
A development and feasibility study evaluating real-time assessment methods for craving, use, and abstinence in outpatient individuals with …
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects
This clinical trial evaluated whether yohimbine and hydrocortisone influence opioid-seeking behavior in individuals with heroin dependence a…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder [Phase 3]
This document reports an update on a Phase 3 safety and tolerability study of depot buprenorphine in individuals seeking treatment for opioi…
-
CLINICAL_TRIALS trial_result · 2018-03-26Clinical Trial Update: Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers [Phase 1]
Phase 1 pharmacokinetic study evaluating intranasal nalmefene in healthy volunteers, with relevance to opioid-related disorders.
-
CLINICAL_TRIALS trial_result · 2018-03-23Clinical Trial Update: Nasal Human Abuse Potential of PTI-821 [Phase 1]
A Phase 1 clinical trial update reports results on the nasal abuse potential of PTI-821 in nondependent opioid users.
-
CLINICAL_TRIALS trial_result · 2018-03-09Clinical Trial Update: Comparison of Naloxone Pharmacokinetics [Phase 1]
Phase 1 study comparing naloxone pharmacokinetics in individuals with opioid use disorder has completed.
-
FDA approval · 2018-03-05FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., expanding its regulatory labeling.
-
FDA approval · 2018-02-01FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV (buprenorphine and naloxone) from Orexo US, Inc. This action updates the product's label…
-
FDA approval · 2018-02-01FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride, a generic product from Hikma Pharmaceuticals USA Inc., expanding its av…
-
FDA approval · 2018-02-01FDA Approved: METHADOSE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for Methadose (methadone hydrochloride) submitted by SpecGx LLC.
-
FDA approval · 2018-02-01FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
FDA approved a supplemental application for SUBOXONE (buprenorphine and naloxone) submitted by Indivior Inc.
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine hydrochloride from PAI Holdings/PAI Pharma for a generic product.
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal's supplemental application for buprenorphine HCl and naloxone HCl (buprenorphine and naloxone) under ANDA203136. The…
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine and naloxone from Actavis Pharma, Inc.
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for buprenorphine from Actavis Pharma, Inc. under an approved ANDA, reflecting an added or updat…
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for a buprenorphine and naloxone product, validating its use as …
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application from Hikma Pharmaceuticals USA Inc. to market a generic buprenorphine hydrochloride and naloxone…
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental ANDA for a generic buprenorphine and naloxone product manufactured by PAI Holdings, expanding access to this opi…